message
stringlengths
3
12.9k
message_type
stringclasses
3 values
message_id
int64
0
2
conversation_id
int64
54.3k
898k
cluster
float64
91
91
__index_level_0__
int64
162k
2.69M
Cell-based therapy to reduce mortality from COVID-19: Systematic review and meta-analysis of human studies on acute respiratory distress syndrome
output
1
79,760
91
238,871
Severe cases of COVID-19 infection, often leading to death, have been associated with variants of acute respiratory distress syndrome (ARDS). Cell therapy with mesenchymal stromal cells (MSCs) is a potential treatment for COVID-19 ARDS based on preclinical and clinical studies supporting the concept that MSCs modulate ...
input
2
79,760
91
238,872
Please summerize the given abstract to a title
instruction
0
79,849
91
239,137
The Use of Standardized Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients (BeeCovid2): A Structured Summary of a Study Protocol for a Randomized Controlled Trial
output
1
79,849
91
239,138
Background: The 2019 coronavirus disease (COVID-19) pandemic continues to spread and affects large numbers of people with unprecedented impacts. To date, there is no consensus on a specific treatment. Experimental evidence has already been obtained for use of the standardized extract of Brazilian green propolis (EPP-AF...
input
2
79,849
91
239,139
Please summerize the given abstract to a title
instruction
0
80,029
91
239,677
Ivermectin: a mini-review
output
1
80,029
91
239,678
Introduction: Avermectins are common antiparasitic drugs, derived from Streptomyces bacteria that exhibit activity against arthropods and nematodes. Ivermectin, an avermectin derivative, is used as a treatment for parasitic infections in humans and domesticated animals.Discussion: Ivermectin's mechanism of action invol...
input
2
80,029
91
239,679
Please summerize the given abstract to a title
instruction
0
80,161
91
240,073
Tocilizumab for the Treatment of COVID-19-Induced Cytokine Storm and Acute Respiratory Distress Syndrome: A Case Series From a Rural Level 1 Trauma Center in Western Pennsylvania
output
1
80,161
91
240,074
An outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus-2, initially in December 2019 at Wuhan, China, subsequently spread around the world. We describe a case series of COVID-19 patients treated at our academic medical center with focus on cytokine storm and potential...
input
2
80,161
91
240,075
Please summerize the given abstract to a title
instruction
0
80,246
91
240,328
Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak.
output
1
80,246
91
240,329
BACKGROUND The outcome is reported of a prospective uncontrolled study based on a stepwise treatment protocol during an outbreak of severe acute respiratory syndrome (SARS) in Hong Kong. METHOD One hundred and thirty eight patients were treated with broad spectrum antibiotics, a combination of ribavirin and low dose co...
input
2
80,246
91
240,330
Please summerize the given abstract to a title
instruction
0
80,267
91
240,391
Appropriate use of tocilizumab in COVID-19 infection
output
1
80,267
91
240,392
OBJECTIVE: This study aimed to describe the effectiveness and optimum use of tocilizumab (TCZ) treatment by the support of clinical, laboratory and radiologic observations. METHODS: All patients were followed up in the hospital with daily interleukin-6 (IL-6), C-reactive protein (CRP), ferritin, d-dimer, full blood cou...
input
2
80,267
91
240,393
Please summerize the given abstract to a title
instruction
0
80,282
91
240,436
Treatment strategies for postviral olfactory dysfunction: A systematic review
output
1
80,282
91
240,437
Background: The coronavirus disease 2019 (COVID-19) pandemic has been associated with a dramatic increase in postviral olfactory dysfunction (PVOD) among patients who are infected. A contemporary evidence-based review of current treatment options for PVOD is both timely and relevant to improve patient care. Objective: ...
input
2
80,282
91
240,438
Please summerize the given abstract to a title
instruction
0
80,288
91
240,454
COVID-19 in IBD: The experience of a single tertiary IBD center
output
1
80,288
91
240,455
BACKGROUND: Italy has been one of the most affected countries in the world by COVID-19. There has been increasing concern regarding the impact of COVID-19 on patients with inflammatory bowel disease (IBD), particularly in patients treated with immunosuppressants or biologics. The aim of our study is to understand the i...
input
2
80,288
91
240,456
Please summerize the given abstract to a title
instruction
0
80,318
91
240,544
Mesenchymal stem cells derived from perinatal tissues for treatment of critically ill COVID-19-induced ARDS patients: a case series
output
1
80,318
91
240,545
BACKGROUND: Acute respiratory distress syndrome (ARDS) is a fatal complication of coronavirus disease 2019 (COVID-19). There are a few reports of allogeneic human mesenchymal stem cells (MSCs) as a potential treatment for ARDS. In this phase 1 clinical trial, we present the safety, feasibility, and tolerability of the ...
input
2
80,318
91
240,546
Please summerize the given abstract to a title
instruction
0
80,495
91
241,075
Efficacy and Effect of Inhaled Adenosine Treatment in Hospitalized COVID-19 Patients
output
1
80,495
91
241,076
Lack of specific antiviral treatment for COVID-19 has resulted in long hospitalizations and high mortality rate. By harnessing the regulatory effects of adenosine on inflammatory mediators, we have instituted a new therapeutic treatment with inhaled adenosine in COVID-19 patients, with the aim of reducing inflammation,...
input
2
80,495
91
241,077
Please summerize the given abstract to a title
instruction
0
80,831
91
242,083
Role of Statins in Coronavirus-Related Disease (COVID-19): A Retrospective Cohort Study in Northern Italy
output
1
80,831
91
242,084
INTRODUCTION: The outbreak by SARS-CoV-2 has rapidly spread worldwide. The need for specific treatments to adequately stop the inflammatory response and its sequelae is day by day more urgent and many therapeutic strategies were performed since COVID-19 burst in the last months. Statins were thought to be effective aga...
input
2
80,831
91
242,085
Please summerize the given abstract to a title
instruction
0
80,835
91
242,095
Role of Mycobacterium w for the Treatment of COVID-19: An Observational Study.
output
1
80,835
91
242,096
Background COVID-19 has taken a big toll on the world in terms of morbidity and mortality. The disease may progress in some of the patients leading to trigger of "cytokine storm" which is shown to be associated with adverse outcomes. Heat killed Mycobacterium w (Mw) is a known immunomodulator which is approved for the ...
input
2
80,835
91
242,097
Please summerize the given abstract to a title
instruction
0
80,915
91
242,335
In patients hospitalized with COVID-19, adding azithromycin to usual care did not reduce 28-d mortality.
output
1
80,915
91
242,336
SOURCE CITATION RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021;397:605-12. 33545096.
input
2
80,915
91
242,337
Please summerize the given abstract to a title
instruction
0
81,008
91
242,614
Observational Study of the Efficiency of Treatments in Patients Hospitalized with Covid-19 in Madrid
output
1
81,008
91
242,615
Background Many different treatments were heavily administered to patients with COVID-19 during the peak of the pandemic in Madrid without robust evidence supporting them. Methods We examined the association between sixteen treatments in four groups (steroids, antivirals, antibiotics and immunomodulators) and intubatio...
input
2
81,008
91
242,616
Please summerize the given abstract to a title
instruction
0
81,047
91
242,731
P.0404 Rapid antidepressant response to first-line selective serotonin reuptake inhibitors in post-COVID-19 depression
output
1
81,047
91
242,732
Introduction: Depression was reported in 30–40% of patients at one, three, and six months following COVID-19 [1]. The host immune response to SARS-CoV-2 infection and related severe systemic inflammation seems to be the main mechanism contributing to the development of post-COVID depression. Emerging literature suggest...
input
2
81,047
91
242,733
Please summerize the given abstract to a title
instruction
0
81,092
91
242,866
Infectious diseases
output
1
81,092
91
242,867
What's new in infectious diseases in 2020 ? This year has been marked by the COVID-19 pandemic, prompting a review of the current knowledge on SARS-CoV-2 and its management in this article The results of the Swiss project « PIRATE » indicate non-inferiority between CRP-guided antibiotic durations or fixed 7-day duratio...
input
2
81,092
91
242,868
Please summerize the given abstract to a title
instruction
0
81,276
91
243,418
Efficacy and Safety of Sofosbuvir/Daclatasvir in the Treatment of COVID-19: A Randomized, Controlled Study
output
1
81,276
91
243,419
BACKGROUND: Data from molecular docking, in-vitro experiments and 2 published small clinical studies suggested a potential therapeutic benefit for the anti-hepatitis C drugs, sofosbuvir (SOF) and daclatasvir (DCV), to repurpose for the treatment of COVID-19. We planned this study to evaluate efficacy and safety of dual...
input
2
81,276
91
243,420
Please summerize the given abstract to a title
instruction
0
81,361
91
243,673
Therapeutic Plasma Exchange is Safe and Efficacious in Normalizing Increased Plasma Viscosity Associated with COVID-19
output
1
81,361
91
243,674
BACKGROUND: COVID-19 associated hyperviscosity is a potential driver for the increased rates of thrombotic complications and multi-organ failure associated with severe COVID-19. Limited experience suggests a promising role for Therapeutic Plasma Exchange (TPE) in COVID-19 management based on the hypothesis that clinica...
input
2
81,361
91
243,675
Please summerize the given abstract to a title
instruction
0
81,500
91
244,090
Convalescent plasma in COVID-19: Does use case matter?
output
1
81,500
91
244,091
A randomized controlled trial of convalescent plasma in severe COVID-19 shows no benefits Coronavirus disease 2019 (COVID-19), the disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected millions of individuals worldwide One of the most severe manifestations of COVID-19 is severe pne...
input
2
81,500
91
244,092
Please summerize the given abstract to a title
instruction
0
81,588
91
244,354
Case series of six kidney transplanted patients with COVID-19 pneumonia treated with tocilizumab
output
1
81,588
91
244,355
Few reports described the outcome of kidney transplanted patients (KTs) affected by COVID-19 treated with interleukin-6 receptor inhibitor Tocilizumab (TCZ). We report our case series of 6 KTs with COVID-19 pneumonia who received TCZ: all were of male gender, with a mean age of 55.5±8.4 years, a median time from transp...
input
2
81,588
91
244,356
Please summerize the given abstract to a title
instruction
0
81,663
91
244,579
A HOME-TREATMENT ALGORITHM BASED ON ANTI-INFLAMMATORY DRUGS TO PREVENT HOSPITALIZATION OF PATIENTS WITH EARLY COVID-19: A MATCHED-COHORT STUDY (COVER 2)
output
1
81,663
91
244,580
Background and Aim: While considerable success has been achieved in the management of patients hospitalized with severe coronavirus disease 2019 (COVID-19), far less progress has been made with early outpatient treatment. We assessed whether the implementation of a home treatment algorithm, designed based upon on a pat...
input
2
81,663
91
244,581
Please summerize the given abstract to a title
instruction
0
81,688
91
244,654
Beneficial effect of Arbidol in the management of COVID-19 infection
output
1
81,688
91
244,655
This study analyzed the effect of Arbidol, a broad-spectrum antiviral compound, on the outcomes of COVID-19 patients. Records of 252 COVID-19 patients were retrospectively analyzed from February 13 to February 29, 2020 in 4 inpatient wards in the Cancer Center, Union Hospital, Tongji Medical College of Huazhong Univers...
input
2
81,688
91
244,656
Please summerize the given abstract to a title
instruction
0
81,719
91
244,747
In nonhospitalized, unvaccinated adults with COVID-19, molnupiravir reduced hospitalization or death at 29 d.
output
1
81,719
91
244,748
SOURCE CITATION Jayk Bernal A, Gomes da Silva MM, Musungaie DB, et al. Molnupiravir for oral treatment of Covid-19 in nonhospitalized patients. N Engl J Med. 2022;386:509-20. 34914868.
input
2
81,719
91
244,749
Please summerize the given abstract to a title
instruction
0
81,790
91
244,960
CLL-370: The Prolonged Positivity of SARS-CoV-2 RNA in Chronic Lymphocytic Leukemia Patients
output
1
81,790
91
244,961
Context Coronavirus disease 2019 (COVID-19) is a highly infectious disease. A small proportion of COVID patients are positive for SARS-CoV-2 for long time. We report a COVID-19 patient with prolonged presence of SARS-CoV-2 RNA. Objective In this study we evaluate the unexpected evolution of patients with CLL diagnosed ...
input
2
81,790
91
244,962
Please summerize the given abstract to a title
instruction
0
81,905
91
245,305
The Anti-Coronavirus Therapy (ACT) trials: design, baseline characteristics, and challenges.
output
1
81,905
91
245,306
BACKGROUND: Effective treatments for COVID-19 are urgently needed but conducting randomized trials during the pandemic has been challenging. METHODS: The Anti-Coronavirus Therapy (ACT) trials are parallel factorial international trials that aimed to enroll 3,500 outpatients and 2,500 inpatients with symptomatic COVID-1...
input
2
81,905
91
245,307
Please summerize the given abstract to a title
instruction
0
81,908
91
245,314
Outcomes of a COVID‐19 recovery program for patients hospitalized with SARS‐CoV‐2 infection in New York City: A prospective cohort study
output
1
81,908
91
245,315
BACKGROUND: In the spring of 2020, New York City was an epicenter of coronavirus disease 2019 (COVID‐19). The post‐hospitalization needs of COVID‐19 patients were not understood and no outpatient rehabilitation programs had been described. OBJECTIVE: To evaluate whether a virtual rehabilitation program would lead to im...
input
2
81,908
91
245,316
Please summerize the given abstract to a title
instruction
0
82,018
91
245,644
Recommendations for the recognition, diagnosis, and management of long COVID: a Delphi study
output
1
82,018
91
245,645
BACKGROUND: In the absence of research into therapies and care pathways for long COVID, guidance based on ‘emerging experience’ is needed. AIM: To provide a rapid expert guide for GPs and long COVID clinical services. DESIGN AND SETTING: A Delphi study was conducted with a panel of primary and secondary care doctors. M...
input
2
82,018
91
245,646
Please summerize the given abstract to a title
instruction
0
82,170
91
246,100
Implications of interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with multiple myeloma
output
1
82,170
91
246,101
Cancer patients are at a higher risk of “Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)” infection than patients without cancer In particular, Multiple Myeloma (MM) patients are at serious risk of contracting this severe infection because of many factors, such as immunosuppression, comorbidities, immune d...
input
2
82,170
91
246,102
Please summerize the given abstract to a title
instruction
0
82,173
91
246,109
Managing comorbidities in Covid-19 patients: A drug utilization study in a COVID-dedicated hospital in Northern India
output
1
82,173
91
246,110
INTRODUCTION: In the prevailing COVID-19 pandemic, the Indian healthcare system has worked hard towards restricting the adverse outcomes to the least possible figures. The present study aims to share the experience of a COVID-dedicated tertiary care government hospital in Northern India of managing COVID-19 patients wi...
input
2
82,173
91
246,111
Please summerize the given abstract to a title
instruction
0
82,175
91
246,115
Renin-angiotensin-system inhibitors and all-cause mortality in patients with coronavirus disease 2019: a systematic review and meta-analysis of observational studies.
output
1
82,175
91
246,116
AIMS We sought to evaluate the association of angiotensin-converting-enzyme inhibitors (ACEI) or AT1 blockers (ARB) therapy with clinical outcomes in patients with coronavirus disease 2019 (COVID-19). METHODS AND RESULTS Electronic databases were searched to identify published studies that reported clinical outcomes in...
input
2
82,175
91
246,117
Please summerize the given abstract to a title
instruction
0
82,313
91
246,529
Tocilizumab for the treatment of COVID-19 among hospitalized patients: A matched retrospective cohort analysis
output
1
82,313
91
246,530
BACKGROUND: There is currently no single treatment that mitigates all harms caused by SARS-CoV-2 infection. Tocilizumab, an interleukin-6 antagonist, may have a role as adjunctive immune-modulating therapy. METHODS: This was an observational, retrospective study of hospitalized adult patients with confirmed COVID-19. T...
input
2
82,313
91
246,531
Please summerize the given abstract to a title
instruction
0
82,336
91
246,598
Another step toward final call on Remdesivir efficacy as a treatment for hospitalized COVID-19 patients: a multicenter open-label trial
output
1
82,336
91
246,599
IntroductionAfter emerging the global pandemic of SARS-CoV2 some preliminary studies demonstrated the efficacy of antiviral treatments. But shortly thereafter, inconsistencies in the results of further clinical trials raised doubts on the efficacy of these agents. In this study, we aimed to evaluate the effect of Remde...
input
2
82,336
91
246,600
Please summerize the given abstract to a title
instruction
0
82,422
91
246,856
POSA21 An In-Hospital Study to Trace the Risk Factors Associated with Adverse Drug Reactions during the Second Wave of COVID-19 in a Secondary Care Hospital in India
output
1
82,422
91
246,857
Objectives: To characterize the adverse drug reactions (ADRs) and the risk factors associated with COVID -19 treatment in a secondary care hospital in South India. Methods: A prospective observational study was carried out on 327 patients admitted between April 1 and May 15, 2021, using an in-person surveillance system...
input
2
82,422
91
246,858
Please summerize the given abstract to a title
instruction
0
82,511
91
247,123
Clinical impact of combination therapy with baricitinib, remdesivir, and dexamethasone in patients with severe COVID-19
output
1
82,511
91
247,124